Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 2379317Generated: October 27, 2026

Triethylamine → N-[3(R,S)-5-cyclohexyl-2,3-dihydro-1-(2-methylpropyl)-2-oxo-1H-1,4-benzodiazepin-3-yl] N'-[3-tetrazol-5-ylphenyl]urea

https://huagongshe.com/reaction/2379317

Reaction equation

Participants

RoleNameHCIDCharge
ReactantTriethylamineHCID 8471—
ReactantTriphosgeneHCID 94429—
Reactant5-Cyclohexyl-1,3-dihydro-1-(2-methylpropyl)-3(R,S)-[(benzyloxycarbonyl)amino]-2H-1,4-benzodiazepin-2-oneHCID 18957779—
Reactant3-(2H-tetrazol-5-yl)-phenylamine hydrochlorideHCID 21201991—
ReactantAminobenzodiazepineHCID 21955614—
CatalystPalladiumHCID 23938—
SolventAcetic AcidHCID 176—
SolventTetrahydrofuranHCID 8028—
SolventEthyl AcetateHCID 8857—
SolventFormic acid methanolHCID 18963719—
ProductN-[3(R,S)-5-cyclohexyl-2,3-dihydro-1-(2-methylpropyl)-2-oxo-1H-1,4-benzodiazepin-3-yl] N'-[3-tetrazol-5-ylphenyl]ureaHCID 17844869950.4%

Reaction Steps

5-Cyclohexyl-1,3-dihydro-1-(2-methylpropyl)-3(R,S)-[(benzyloxycarbonyl)amino]-2H-1,4-benzodiazepin-2-one (1.0 g, 2.23 mmol) was dissolved in formic acid/methanol (130 ml of a 4.5% (v/v) solution), and added over 5 min to a stirred suspension of 10% palladium on carbon (0.36 g, 36% (w/w)) in formic acid/methanol (27 ml of a 4.5% (v/v) solution). After 4 h at room temperature the catalyst was filtered off and washed sequentially with methanol and acetone. The flitrate was evaporated in vacuo and the solid residue partitioned between ethyl acetate (500 ml) and 10% sodium carbonate solution (500 ml). The organic phase was dried (Na2SO4) and evaporated to give a clear oil, which was used without further purification. To a suspension of 5-(3-aminophenyl)tetrazole hydrochloride (0.29 g, 1.45 mmol) in tetrahydrofuran (10 ml) was added triethylamine (0.4 ml, 2.9 mmol). The mixture was cooled in an ice bath and triphosgene (0.14 g, 0.48 mmol) added, followed by triethylamine (0.3 ml, 2.2 mmol). The ice bath was removed and the mixture stirred at room temperature for 30 min. A solution of the aminobenzodiazepine (0.35 g, 1.11 mmol), from the above procedure, in tetrahydrofuran (15 ml) was added dropwise to the mixture. The reaction mixture was stirred at room temperature for 2 h, then diluted with ethyl acetate (30 ml) followed by 20% aqueous acetic acid (30 ml). After stirring for a further 15 min a white precipitate was filtered off and washed with ethyl acetate. The solid was suspended in methanol (20 ml), heated to 50° C., then filtered hot to afford N-[3(R,S)-5-cyclohexyl-2,3-dihydro-1-(2-methylpropyl )-2-oxo-1H-1,4-benzodiazepin-3-yl] N'-[3-tetrazol-5-ylphenyl]urea (280 mg, 39%) as a white solid. mp 188°-190° C. 1H NMR (360 MHz, D6 -DMSO) δ 0.65 (3H, d, J=7 Hz), 0.76 (3H, d, J=7 Hz), 0.99-1.96 (11H, m), 2.97 (1H, m), 3.62 (1H, dd, J=14 and 5 Hz), 4.15 (1H, dd, J=14 and 9 Hz), 5.05 (1H, m), 7.36-7.69 (7H, m), 7.78 (1H, d, J=8 Hz), 8.15 (1H, s), 9.23 (1H, s).

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS05360802
Source datasetuspto-grants-1994_11
ORD IDord-84afb67952bc45d39cf68da0055109a7
Source noteuspto-grants-1994_11